Story
Definium Therapeutics Stock Surges 20% on Positive Phase 3 Anxiety Drug Trial Data

Definium Therapeutics (NASDAQ:DFTX) shares surged 20% in Wednesday's pre-market trading after the company announced positive topline results from its Phase 3 Voyage study. The trial, which evaluated the drug candidate DT120 ODT for treating generalized anxiety disorder (GAD), successfully met its primary endpoint and all key secondary efficacy endpoints.
Trial Meets All Endpoints
The study's primary endpoint was the change in the Hamilton Anxiety Rating Scale (HAM-A) score from baseline. According to Definium, participants receiving DT120 ODT achieved a statistically significant reduction in their HAM-A score compared to those on placebo.
The company reported a placebo-adjusted change of -5.4 points from baseline at Week 12, a result with high statistical significance (p<0.0001). The mean change from baseline was -11.6 for the DT120 ODT group, compared with -6.2 for the placebo group. The treatment also demonstrated rapid efficacy, with improvements observed as early as Day 2 and sustained throughout the trial.
AdSafety Profile and Next Steps
DT120 ODT was generally well tolerated in the study, which enrolled 214 participants across approximately 35 sites in the United States. Treatment-emergent adverse events were reported as mild to moderate in severity and transient. Importantly, Definium stated that no new safety signals were identified, and there was no evidence of a suicidality signal or suicidal behavior.
For investors, this marks the second positive Phase 3 readout for the DT120 ODT program. In June, the company announced positive results for the drug candidate in a trial for major depressive disorder. Definium expects topline results from its second Phase 3 study in GAD, called Panorama, in September, which will be a key upcoming catalyst for the company.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.